Mathilde Hunault-Berger

Featured in: Favicon

Articles

Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia - Leukemia

4 days ago | nature.com | Delphine Lebon |Nicolas Duployez |Christophe Willekens |Thomas Cluzeau |Christian Récher |Mathilde Hunault-Berger | +1 more

AbstractFront-line treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in patients with low-/intermediate-risk acute promyelocytic leukemia (APL). However, for high-risk (HR) patients (defined as those with a white blood cell count ≥ 10×10⁹/L), the role of ATRA-ATO is subject to debate, and study data are scarce.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.